



POSTER PRESENTATION

Open Access

Influence of variants of Fcg receptor IIA on the European league against rheumatism responses to anti-tumour necrosis factor alpha therapy in psoriatic arthritis

J Ramirez^{1*}, J L Fernandez-Sueiro⁴, R Lopez², C Montilla, B Suarez², C Moll¹, R Rodriguez², F Blanco⁴, M Alsina³, R Sanmarti¹, F Lozano², J Cañete¹

From 5th European Workshop on Immune-Mediated Inflammatory Diseases Sitges-Barcelona, Spain. 1-3 December 2010

Introduction

The efficacy of biological therapies currently used in psoriatic arthritis depends not only on their blocking effect on the targeted molecule but also on the affinity of genetically defined variants of the Fc-gamma receptors for the constant portion (Fc fragment of IgG1).

Aim

To determine whether polymorphisms in Fc-gamma receptor IIA influence clinical efficacy in patients with psoriatic arthritis treated with tumor necrosis factor alpha inhibitors.

Patients and methods

The study population comprised 110 patients (52.7% males and 47.3% females) with psoriatic arthritis refractory to 15 mg or more of methotrexate/week. Infliximab (33.6%), etanercept (50.9%) or adalimumab (15.5%) were initiated, and patients were evaluated after 12 and 24 weeks using the EULAR response criteria. Genotyping of FCGR IIA-H131R polymorphism was performed by allele-specific PCR and PCR sequence-based typing. The chi-square test was used to compare response rates across Fc-gamma receptor IIA genotype.

Results

No significant differences were found at 12 and 24 weeks in EULAR responses between patients with high affinity alleles (FCGRIIA HH/HR) and patients with low

affinity alleles (FCGRIIA RR) (Tables 1 and 2). However, there was a trend to a better response among patients with high affinity alleles.

Conclusion

These results suggest that FCGR IIA-H131R polymorphism has low influence in the clinical efficacy of anti-TNF therapies in patients with psoriatic arthritis. Although different to previously reported results in rheumatoid arthritis [1], these results can be explained because of the better and more prolonged response to anti-TNF therapy in psoriatic arthritis than in rheumatoid arthritis. In addition, in this study we analyzed patients with three different anti-TNF-alpha therapies.

Table 1 12 weeks EULAR Response FCGRIIA

| | HH+HR | RR | Total |
|--------------|-------|------|-------|
| Null (%) | 10.1 | 26.3 | 13.3 |
| Moderate (%) | 27.8 | 10.5 | 24.5 |
| Good (%) | 62.0 | 63.2 | 62.2 |

p = 0.086.

Table 2 24 weeks EULAR response FCGRIIA

| | HH+HR | RR | Total |
|--------------|-------|------|-------|
| Null (%) | 8.9 | 26.3 | 13.3 |
| Moderate (%) | 27.8 | 15.8 | 25.5 |
| Good (%) | 63.3 | 57.9 | 62.2 |

p = 0.090.

¹Rheumatology, Hospital Clinic, Barcelona, Spain
Full list of author information is available at the end of the article

Author details

¹Rheumatology, Hospital Clinic, Barcelona, Spain. ²Immunology, Hospital Clinic, Barcelona, Spain. ³Hospital Clinic, Barcelona, Spain. ⁴Rheumatology, Complejo Hospitalario Juan Canalejo, La Coruña, Spain.

Published: 25 November 2010

Reference

1. Cañete JD, *et al.*: *Ann Rheum Dis.* 2009, **68**:1547-52.

doi:10.1186/1479-5876-8-S1-P38

Cite this article as: Ramirez *et al.*: Influence of variants of Fcγ receptor IIA on the European league against rheumatism responses to anti-tumour necrosis factor alpha therapy in psoriatic arthritis. *Journal of Translational Medicine* 2010 **8**(Suppl 1):P38.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

